cysteine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 769 | 52-90-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Oct. 22, 1986 | FDA | HOSPIRA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| CHEBI has role | CHEBI:78675 | fundamental metabolites |
| CHEBI has role | CHEBI:64577 | dough improvers |
| CHEBI has role | CHEBI:77703 | EC 4.3.1.3 inhibitors |
| CHEBI has role | CHEBI:77746 | Homo sapiens metabolite |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Bronchiectasis | indication | 12295008 | DOID:9563 |
| Amyloidosis | indication | 17602002 | DOID:9120 |
| Bronchitis | indication | 32398004 | DOID:6132 |
| General anesthesia | indication | 50697003 | |
| Poisoning by acetaminophen | indication | 70273001 | |
| Cystic fibrosis of the lung | indication | 86555001 | |
| Thick Bronchial Secretions | indication | ||
| Contrast Media-Induced Nephrotoxicity Prevention | indication | ||
| Atelectasis due to Mucous Obstruction | indication | ||
| Meconium ileus | off-label use | 206523001 | |
| Bronchial Studies | off-label use | ||
| Bronchospasm | contraindication | 4386001 | |
| Classical phenylketonuria | contraindication | 7573000 | |
| Peptic ulcer | contraindication | 13200003 | DOID:750 |
| Esophageal varices | contraindication | 28670008 | |
| Gastrointestinal ulcer | contraindication | 40845000 | |
| Low blood pressure | contraindication | 45007003 | |
| Gastrointestinal hemorrhage | contraindication | 74474003 | |
| Decreased respiratory function | contraindication | 80954004 | |
| Acute exacerbation of asthma | contraindication | 708038006 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 1.82 | acidic |
| pKa2 | 10.19 | acidic |
| pKa3 | 8.8 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 500MG/10ML (50MG/ML) | ELCYS | EXELA PHARMA | N210660 | April 16, 2019 | RX | SOLUTION | INTRAVENOUS | 10478453 | Jan. 15, 2039 | METHOD OF USING L-CYSTEINE IN AN ADMIXTURE FOR TREATING PATIENTS NEEDING PARENTERAL NUTRITION |
| 500MG/10ML (50MG/ML) | ELCYS | EXELA PHARMA | N210660 | April 16, 2019 | RX | SOLUTION | INTRAVENOUS | 10583155 | Jan. 15, 2039 | METHOD OF USING L-CYSTEINE IN AN ADMIXTURE FOR TREATING PATIENTS NEEDING PARENTERAL NUTRITION |
| 500MG/10ML (50MG/ML) | ELCYS | EXELA PHARMA | N210660 | April 16, 2019 | RX | SOLUTION | INTRAVENOUS | 11510942 | Jan. 15, 2039 | METHOD OF USING L-CYSTEINE IN AN ADMIXTURE FOR TREATING PATIENTS NEEDING PARENTERAL NUTRITION |
| 500MG/10ML (50MG/ML) | NOURESS | BAXTER HLTHCARE CORP | N212535 | Dec. 13, 2019 | DISCN | SOLUTION | INTRAVENOUS | 10478453 | Jan. 15, 2039 | METHOD OF USING L-CYSTEINE IN AN ADMIXTURE FOR TREATING PATIENTS NEEDING PARENTERAL NUTRITION |
| 500MG/10ML (50MG/ML) | NOURESS | BAXTER HLTHCARE CORP | N212535 | Dec. 13, 2019 | DISCN | SOLUTION | INTRAVENOUS | 10583155 | Jan. 15, 2039 | METHOD OF USING L-CYSTEINE IN AN ADMIXTURE FOR TREATING PATIENTS NEEDING PARENTERAL NUTRITION |
| 500MG/10ML (50MG/ML) | NOURESS | BAXTER HLTHCARE CORP | N212535 | Dec. 13, 2019 | DISCN | SOLUTION | INTRAVENOUS | 11510942 | Jan. 15, 2039 | METHOD OF USING L-CYSTEINE IN AN ADMIXTURE FOR TREATING PATIENTS NEEDING PARENTERAL NUTRITION |
| 500MG/10ML (50MG/ML) | NOURESS | BAXTER HLTHCARE CORP | N212535 | Dec. 13, 2019 | DISCN | SOLUTION | INTRAVENOUS | 10543186 | March 15, 2039 | METHOD OF INTRAVENOUSLY ADMINISTERING A DILUTED CYSTEINE HYDROCHLORIDE SOLUTION TO A NEONATE IN NEED THEREOF |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Cystine/glutamate transporter | Transporter | Ki | 4.23 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4031437 | VUID |
| N0000184609 | NUI |
| D00026 | KEGG_DRUG |
| 7048-04-6 | SECONDARY_CAS_RN |
| 221086 | RXNORM |
| 4018687 | VANDF |
| 4019702 | VANDF |
| 4031437 | VANDF |
| C0010654 | UMLSCUI |
| CHEBI:15356 | CHEBI |
| BTC | PDB_CHEM_ID |
| CHEMBL863 | ChEMBL_ID |
| CHEMBL54943 | ChEMBL_ID |
| 5862 | PUBCHEM_CID |
| DB00151 | DRUGBANK_ID |
| CHEMBL1200630 | ChEMBL_ID |
| D003545 | MESH_DESCRIPTOR_UI |
| 6162 | INN_ID |
| 4782 | IUPHAR_LIGAND_ID |
| K848JZ4886 | UNII |
| 11233 | MMSL |
| 4524 | MMSL |
| 7452 | MMSL |
| d04181 | MMSL |
| 000934 | NDDF |
| 004536 | NDDF |
| 108949008 | SNOMEDCT_US |
| 108950008 | SNOMEDCT_US |
| 5932006 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| ProcalAmine | HUMAN PRESCRIPTION DRUG LABEL | 22 | 0264-1915 | INJECTION | 0.01 g | INTRAVENOUS | NDA | 24 sections |
| TrophAmine | HUMAN PRESCRIPTION DRUG LABEL | 20 | 0264-1933 | SOLUTION | 0.02 g | INTRAVENOUS | NDA | 23 sections |
| TrophAmine | HUMAN PRESCRIPTION DRUG LABEL | 20 | 0264-1933 | SOLUTION | 0.02 g | INTRAVENOUS | NDA | 23 sections |
| TrophAmine | HUMAN PRESCRIPTION DRUG LABEL | 20 | 0264-1933 | SOLUTION | 0.02 g | INTRAVENOUS | NDA | 23 sections |
| FreAmine III | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0264-9010 | INJECTION, SOLUTION | 0.02 g | INTRAVENOUS | NDA | 24 sections |
| FreAmine III | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0264-9011 | INJECTION, SOLUTION | 0.02 g | INTRAVENOUS | NDA | 24 sections |
| TrophAmine | HUMAN PRESCRIPTION DRUG LABEL | 20 | 0264-9341 | SOLUTION | 0.02 g | INTRAVENOUS | NDA | 23 sections |
| TrophAmine | HUMAN PRESCRIPTION DRUG LABEL | 20 | 0264-9361 | SOLUTION | 0.02 g | INTRAVENOUS | NDA | 23 sections |
| HepatAmine | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0264-9371 | INJECTION, SOLUTION | 0.01 g | INTRAVENOUS | NDA | 23 sections |
| Premasol - sulfite-free (Amino Acid) | HUMAN PRESCRIPTION DRUG LABEL | 19 | 0338-1130 | INJECTION, SOLUTION | 0.02 g | INTRAVENOUS | ANDA | 15 sections |
| Premasol - sulfite-free (Amino Acid) | HUMAN PRESCRIPTION DRUG LABEL | 19 | 0338-1130 | INJECTION, SOLUTION | 0.02 g | INTRAVENOUS | ANDA | 15 sections |
| Premasol - sulfite-free (Amino Acid) | HUMAN PRESCRIPTION DRUG LABEL | 19 | 0338-1130 | INJECTION, SOLUTION | 0.02 g | INTRAVENOUS | ANDA | 15 sections |
| Premasol - sulfite-free (Amino Acid) | HUMAN PRESCRIPTION DRUG LABEL | 19 | 0338-1131 | INJECTION, SOLUTION | 0.01 g | INTRAVENOUS | ANDA | 15 sections |
| Premasol - sulfite-free (Amino Acid) | HUMAN PRESCRIPTION DRUG LABEL | 19 | 0338-1131 | INJECTION, SOLUTION | 0.01 g | INTRAVENOUS | ANDA | 15 sections |
| Premasol - sulfite-free (Amino Acid) | HUMAN PRESCRIPTION DRUG LABEL | 19 | 0338-1131 | INJECTION, SOLUTION | 0.01 g | INTRAVENOUS | ANDA | 15 sections |
| CYSTEINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0338-9645 | INJECTION | 34.50 mg | INTRAVENOUS | NDA | 19 sections |
| CYSTEINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0338-9645 | INJECTION | 34.50 mg | INTRAVENOUS | NDA | 19 sections |
| ELCYS | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51754-1007 | INJECTION, SOLUTION | 10 mg | INTRAVENOUS | NDA | 20 sections |
| Nouress | HUMAN PRESCRIPTION DRUG LABEL | 1 | 76014-006 | INJECTION | 34.50 mg | Intravenous | NDA | 19 sections |